Digital health and wellness company Hims & Hers is investing more than $200 million to expand its operations in New Albany ...

The transaction closure is anticipated in early 2026, contingent on regulatory approvals and other customary conditions.

Hims & Hers Health (HIMS) has entered into an agreement to acquire YourBio Health, a Boston-based maker of capillary whole blood sampling technology.

Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...

Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Hims & Hers Health, Inc. (HIMS) reports results for the quarter ended September 2025. While this widely-known ...

Supported by strong balance sheet, program provides flexibility for Company to capitalize on valuation disconnects over the next three years SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall health and identify ways to ...